1. Introduction

Drug-induced organ toxicity remains the leading cause of clinical trial failure and post-market drug withdrawal. Hepatotoxicity, cardiotoxicity, and nephrotoxicity account for the majority of adverse drug reactions, yet current preclinical models—including animal studies and conventional 2D cell cultures—fail to predict these toxicities with adequate accuracy. Organoids and organ-on-chip (OoC) platforms provide human-relevant, tissue-specific models that capture the complex cellular interactions, metabolic pathways, and physiological responses underlying organ toxicity. This article presents detailed technical protocols for toxicity profiling across three critical organ systems, including specific experimental parameters, analytical methods, and data interpretation frameworks.

Related resources: Toxicity screening services | Organ-on-chip toxicity models

2. Hepatotoxicity Profiling with Liver Organoids and Liver-on-Chip

2.1 Liver Organoid Models for Drug-Induced Liver Injury (DILI)

Drug-induced liver injury (DILI) is the most common reason for drug withdrawal and black-box warnings, accounting for approximately 50% of acute liver failure cases in the United States. Liver organoids derived from human iPSCs or primary hepatocytes recapitulate key hepatic functions including albumin and urea synthesis, CYP450-mediated drug metabolism, and bile acid transport. Mun et al. (2019) demonstrated that liver organoids could successfully verify the hepatotoxicity of drugs withdrawn from the market, including troglitazone and trovafloxacin, at clinically relevant concentrations. Mekky et al. (2021) applied human liver organoids to test the toxicity of aspartic acid-coated magnesium oxide nanoparticles and valproate, showing reduced cell viability, decreased ATP, and increased reactive oxygen species (ROS) consistent with clinical hepatotoxicity profiles.

For hepatotoxicity screening, iPSC-derived liver organoids are cultured in hepatic maturation medium (HepatoZYME-SFM supplemented with 20 ng/mL oncostatin M, 0.1 µM dexamethasone, and 1% DMSO) for 14–21 days to achieve mature hepatic phenotype. Mature organoids exhibit CYP3A4 activity >50 pmol/min/mg protein and albumin secretion >50 µg/mL/day, comparable to primary human hepatocytes. Drug exposure is initiated at 70–80% confluence to ensure adequate metabolic capacity.

2.2 Liver-on-Chip for Chronic and Idiosyncratic DILI

Static liver organoid cultures, while useful for acute toxicity, may not fully capture the progressive metabolic and inflammatory changes underlying chronic or idiosyncratic DILI. Liver-on-chip platforms address this limitation by enabling long-term culture (4–8 weeks) under physiological perfusion (0.5–2 µL/min) with co-cultured endothelial and Kupffer cells. Shroff et al. (2022) reviewed liver-on-chip systems for toxicity assessment, noting that these platforms maintain CYP enzyme expression and bile canaliculi formation over extended periods, enabling detection of toxicity that emerges only after repeated drug exposure.

2.3 Experimental Protocol for Hepatotoxicity Screening

Key hepatotoxicity endpoints measured on liver-chip include:

Experimental Protocol for Hepatotoxicity Screening:

Step 1: Preparation — Liver organoids (day 14–21 post-differentiation) are dissociated into 50–100 µm fragments using TrypLE for 5 minutes at 37°C. Fragments are resuspended in hepatic medium at 2 × 10⁵ cells/mL.

Step 2: Plating — 50 µL of organoid suspension is seeded into each well of a 384-well plate pre-coated with Matrigel (1:20 dilution). Plates are incubated at 37°C, 5% CO2 for 24 hours to allow re-aggregation.

Step 3: Drug Exposure — Test compounds are prepared as 10 mM DMSO stocks and diluted in hepatic medium. Compounds are tested in 8-point dose-response (1:3 dilution, 0.1–100 µM) with positive controls: acetaminophen (APAP, 10 mM, known hepatotoxin), troglitazone (50 µM, withdrawn drug), and staurosporine (1 µM, general cytotoxin). Negative controls receive 0.1% DMSO vehicle.

Step 4: Incubation — Plates are incubated for 24, 48, and 72 hours to capture time-dependent toxicity. For chronic studies, media and drugs are replenished every 48 hours for up to 14 days.

Step 5: Endpoint Analysis — At each timepoint, supernatants are collected for LDH and albumin assays. Organoids are lysed for ATP, ROS, and GSH measurements. Live/dead staining (calcein-AM/ethidium homodimer-1) is performed for high-content imaging.

Step 6: Data Analysis — IC50 values are calculated from dose-response curves. Compounds are classified by DILI risk: IC50 < 10 µM (high risk), 10–50 µM (moderate risk), >50 µM (low risk). The benchmark dose (BMD) approach calculates the dose producing a 10% response change (BMD10) relative to controls, providing a more sensitive threshold than NOAEL.

Related resource: Liver organoid products

3. Cardiotoxicity Profiling with Cardiac Organoids and Heart-on-Chip

3.1 Cardiac Organoid Models

Cardiotoxicity is the second leading cause of drug withdrawal and clinical trial termination, with an estimated annual cost of $2.9 billion to the pharmaceutical industry. Cardiac organoids derived from human iPSCs offer a human-relevant platform for assessing drug-induced cardiotoxicity, including QT prolongation, arrhythmia, contractile dysfunction, and structural cardiomyopathy. Eder et al. (2016) established protocols for heart organoid generation, demonstrating spontaneous contractility, sarcomere organization, and electrophysiological properties comparable to native cardiac tissue. Richards et al. (2020) used heart organoids to model hypoxia-enhanced doxorubicin cardiotoxicity, showing that hypoxic cardiac injury aggravates the cardiotoxicity of doxorubicin—a finding with significant clinical relevance for cancer patients with pre-existing cardiovascular conditions.

Cardiac organoids are generated from iPSCs using a directed differentiation protocol: 8 ng/mL BMP4 (days 0–2), 5 µM CHIR99021 (days 1–3), 2 µM Wnt-C59 (days 3–5), and 5 µM IWR-1 (days 5–7) in RPMI/B27 medium. Organoids are maintained in cardiac maintenance medium (RPMI 1640, B27 supplement, 100 µg/mL ascorbic acid, 1% penicillin-streptomycin) for 14–30 days to achieve mature cardiomyocyte phenotype with spontaneous beating rates of 40–80 beats per minute.

3.2 Heart-on-Chip for Electromechanical Assessment

Heart-on-chip platforms integrate iPSC-derived cardiomyocytes within microfluidic devices that enable real-time measurement of contractile force, electrical activity, and calcium handling. These systems provide physiological mechanical cues (cyclic stretch, 5–10%) and electrical stimulation (1–3 Hz) that enhance cardiomyocyte maturation and enable arrhythmia detection.

Key cardiotoxicity endpoints include:

3.3 Experimental Protocol for Cardiotoxicity Screening

Step 1: Cardiac organoid preparation — Day 21–30 iPSC-cardiac organoids are selected for uniform size (200–400 µm diameter) and spontaneous beating. Organoids are plated in 96-well plates (1 organoid per well) or integrated into heart-on-chip devices.

Step 2: Baseline recording — Baseline contractile and electrophysiological parameters are recorded for 5 minutes to establish individual organoid variability. Organoids with irregular rhythms (<30 or >120 bpm) or arrhythmias are excluded.

Step 3: Drug exposure — Compounds are introduced at 8-point concentrations (0.01–100 µM) with positive controls: doxorubicin (1 µM, anthracycline cardiotoxicity), cisapride (1 µM, hERG blockade/QT prolongation), and E-4031 (0.1 µM, positive control for hERG blockade). Negative controls receive 0.1% DMSO.

Step 4: Real-time monitoring — Contractile and electrical parameters are recorded continuously for 24–72 hours using automated video analysis (MotionTracker) or MEA systems. For hERG channel studies, whole-cell patch-clamp recordings measure hERG current (IKr) at −40 mV holding potential with a step-ramp protocol from −50 to +30 mV.

Step 5: Endpoint analysis — At 24 and 72 hours, organoids are stained for troponin T (cTnT), alpha-actinin, and DAPI for structural assessment. Caspase-3/7 activity is measured using luminescent substrates. ROS generation is assessed with CellROX Orange.

Step 6: Data interpretation — QT prolongation risk is assessed by FPDc prolongation >10% at therapeutic concentrations. Arrhythmia risk is scored by the incidence of EADs and Torsades de Pointes (TdP)-like events. A compound is flagged as high cardiotoxicity risk if it produces >50% reduction in contraction amplitude or >20% FPDc prolongation at concentrations <10× the therapeutic plasma concentration (Cmax).

Related resource: Cardiac organoid and heart-on-chip products

4. Nephrotoxicity Profiling with Kidney Organoids and Kidney-on-Chip

4.1 Kidney Organoid Models for Drug-Induced Kidney Injury (DIKI)

The kidney is particularly vulnerable to drug toxicity due to its high blood flow, active tubular secretion, and concentration of xenobiotics in the tubular lumen. Drug-induced kidney injury (DIKI) affects 20–30% of hospitalized patients receiving nephrotoxic drugs. Morizane et al. (2015) demonstrated that kidney organoids derived from human iPSCs develop proximal tubule-like structures with functional expression of megalin, cubilin, and organic anion transporters. When exposed to gentamicin and cisplatin, these organoids exhibited proximal tubular damage and distal tubular toxicity, respectively, recapitulating the site-specific nephrotoxicity observed in patients. Takasato et al. (2015) independently validated human kidney organoids for nephrotoxicity assessment, confirming the predictive value of iPSC-derived renal models.

Kidney organoids are generated from iPSCs using a modified Takasato protocol: 8 µM CHIR99021 (days 0–3), 200 ng/mL FGF9 (days 3–7), and 1 µg/mL heparin in defined kidney differentiation medium. Organoids are maintained in kidney maturation medium (Advanced RPMI, B27, 100 ng/mL BMP7, 10 ng/mL FGF9) for 14–28 days to achieve tubular and glomerular differentiation.

4.2 Kidney-on-Chip with Integrated Sensing

Kidney-on-chip platforms advance nephrotoxicity assessment by integrating proximal tubule cells under physiological shear stress (0.1–2 dyne/cm²) with real-time sensor monitoring. Emulate Bio developed a kidney-on-chip with tissue-embedded microsensors for oxygen, glucose, lactate, and glutamine, providing real-time metabolic assessment of tubular function. This system uncovered a previously unknown mechanism of cisplatin-induced nephrotoxicity involving glucose transport disruption and predicted the protective effects of SGLT2 inhibitors (empagliflozin)—validated retrospectively in a clinical cohort of 247 patients receiving cyclosporine or cisplatin.

Key nephrotoxicity endpoints include:

4.3 Experimental Protocol for Nephrotoxicity Screening

Step 1: Kidney organoid preparation — Day 21–28 kidney organoids with visible tubular structures are selected. Tubular segments are microdissected or whole organoids are dissociated into fragments (50–100 µm) for plating.

Step 2: Plating — Kidney organoid fragments are embedded in Matrigel domes (50 µL/well) in 24-well plates or seeded onto Transwell inserts (0.4 µm pore size) for 2D monolayer studies. For kidney-on-chip, fragments are loaded into the epithelial channel of microfluidic devices and perfused with kidney medium at 0.5 µL/min.

Step 3: Drug exposure — Compounds are prepared at 10 mM stock and diluted in kidney medium. Test concentrations range from 0.1–1000 µM (8-point, 1:3 dilution). Positive controls: cisplatin (10–50 µM, proximal tubular toxin), gentamicin (1–5 mM, proximal tubular toxin), and cyclosporine A (5–25 µM, calcineurin inhibitor nephrotoxicity). Negative controls: 0.1% DMSO.

Step 4: Incubation — Plates are incubated for 24, 48, and 72 hours. For kidney-on-chip, drugs are perfused continuously for 72 hours with media sampling at 24-hour intervals.

Step 5: Endpoint analysis — TEER is measured using chopstick electrodes. Transporter function is assessed by adding fluorescent substrates (10 µM FITC, 100 µM PAH) to the apical or basolateral compartments and measuring fluorescence in the opposing compartment after 60 minutes. Injury biomarkers (KIM-1, NGAL) are quantified by ELISA in 24-hour conditioned media. Cell viability is assessed by ATP (CellTiter-Glo) and LDH release. Histological analysis includes PAS staining (brush border integrity), immunofluorescence for LTL (Lotus tetragonolobus lectin, proximal tubule marker), and TEM for ultrastructural damage (mitochondrial swelling, nuclear condensation).

Step 6: Data analysis — The concentration producing 50% reduction in TEER (TEER-IC50) or 50% increase in KIM-1 (KIM-1-EC50) is calculated. Nephrotoxicity risk classification: high risk (TEER-IC50 < 10 µM), moderate risk (10–100 µM), low risk (>100 µM). Correlation with clinical nephrotoxicity frequency is assessed by comparing predicted risk with FDA adverse event reporting data.

Related resource: Kidney organoid and kidney-on-chip products

5. Multi-Organ Toxicity Assessment

5.1 Systemic Toxicity in Multi-Organ-on-Chip

Many drugs produce toxicity in multiple organs simultaneously, either through direct multi-organ effects or through metabolite-mediated toxicity. McAleer et al. (2019) demonstrated that a liver-heart multi-organ chip could reveal cardiotoxicity of cyclophosphamide metabolites that were not detected in isolated cardiac cultures. Chramiec et al. (2020) showed that multi-organ chips identified clinically relevant resistances to experimental small molecule treatments that were missed in single-organ assays.

Multi-organ toxicity platforms typically integrate liver, heart, kidney, and lung compartments connected by a shared vascular circuit. Novak et al. (2024) developed a dynamic Microphysiological System Chip Platform (MSCP) integrating intestine, liver, heart, and lung for comprehensive toxicity assessment. Drugs are introduced via the intestinal compartment, metabolized by the liver, and distributed to target organs, enabling detection of both parent compound and metabolite toxicity.

5.2 Experimental Design for Multi-Organ Toxicity

Systemic toxicity studies require careful design of flow rates, partitioning coefficients, and sampling strategies. Typical parameters include:

Related resource: Multi-organ-on-chip toxicity platforms

6. Data Analysis and Statistical Considerations

6.1 Dose-Response Modeling

Toxicity data are fitted to sigmoidal dose-response curves (4-parameter logistic) to derive IC50, EC50, and benchmark dose (BMD) values. For organ-specific toxicity, the relative potency factor (RPF) compares the toxicity of test compounds to reference toxicants (e.g., acetaminophen for liver, doxorubicin for heart, cisplatin for kidney).

6.2 In Vitro-In Vivo Extrapolation (IVIVE)

IVIVE converts in vitro toxicity concentrations to predicted in vivo doses using physiological scaling factors: In vivo dose (mg/kg) = (In vitro concentration × Vd) / (F × bioavailability), where Vd is the volume of distribution and F is the fraction unbound in plasma. For liver toxicity, the R value (ratio of in vitro IC50 to therapeutic Cmax) is used: R < 10 indicates high clinical concern, 10–100 moderate concern, >100 low concern.

6.3 Machine Learning Integration

Toxicity profiling generates high-dimensional datasets (viability, function, biomarkers, imaging) that benefit from machine learning integration. Support vector machines (SVM) and random forest classifiers trained on organoid/OoC toxicity data achieve >85% accuracy in predicting clinical DILI outcomes, outperforming traditional animal-based predictions.

Related resource: Data analysis and AI-driven toxicity prediction services

7. Conclusion

Organoid and organ-on-chip technologies provide human-relevant, tissue-specific platforms for hepatotoxicity, cardiotoxicity, and nephrotoxicity profiling. By capturing the complex physiology, metabolism, and injury responses of human tissues, these models enable earlier, more accurate prediction of drug-induced organ toxicity. Integration into multi-organ systems further enhances the detection of systemic and metabolite-mediated toxicities, accelerating the development of safer therapeutics.

Related resources: GBiowit toxicity screening solutions | Custom organoid and organ-on-chip assay development

References

[1] Mun SJ, et al. (2019). Liver organoid toxicity screening of withdrawn drugs. Hepatology. DOI
[2] Mekky RY, et al. (2021). Human liver organoid toxicity testing with nanoparticles and valproate. Toxicology Letters. DOI
[3] Morizane R, et al. (2015). Kidney organoid nephrotoxicity with gentamicin and cisplatin. Nature Communications. DOI
[4] Takasato M, et al. (2015). Human kidney organoids for nephrotoxicity validation. Nature. DOI
[5] Richards DJ, et al. (2020). Heart organoid model of hypoxia‑enhanced doxorubicin cardiotoxicity. Biomaterials. DOI
[6] Eder A, et al. (2016). Cardiac organoid generation and drug screening. Cardiovascular Research. DOI
[7] McAleer CW, et al. (2019). Multi‑organ chip for metabolism‑dependent cardiotoxicity. Lab on a Chip. DOI
[8] Chramiec A, et al. (2020). Clinical resistance prediction using multi‑organ chips. Nature Communications. DOI
[9] Novak et al. (2024). Dynamic microphysiological system for multi‑organ toxicity. Bioactive Materials. DOI
[10] Shroff T, et al. (2022). Multi‑organ chips for toxicity assessment. Nature Reviews Drug Discovery. PubMed Central
[11] van de Wetering M, et al. (2015). Drug‑induced liver failure in clinical trials. Cell. DOI
[12] Jamal R, et al. (2019). Organ toxicity as drug development failure reason. Frontiers in Cell and Developmental Biology. DOI